Clinical pharmacology considerations in biologics development
نویسندگان
چکیده
منابع مشابه
Pralatrexate pharmacology and clinical development.
Folates are well known to be essential for many cellular processes, including cellular proliferation. As a consequence, antifolates, the fraudulent mimics of folic acid, have been shown to be potent therapeutic agents in many cancers. Over the past several decades, efforts to improve on this class of drugs have met with little success. Recently, one analog specifically designed to have high aff...
متن کاملCore Entrustable Professional Activities in Clinical Pharmacology for Entering Residency: Biologics.
Biologicals are a rapidly expanding class of medications used in the treatment of many different conditions. This article reviews the common characteristics of this class and the requirements for safe and effective use in patients. Several vignettes are included to illustrate common challenges.
متن کاملPractical considerations in clinical strategy to support the development of injectable drug-device combination products for biologics
The development of an injectable drug-device combination (DDC) product for biologics is an intricate and evolving process that requires substantial investments of time and money. Consequently, the commercial dosage form(s) or presentation(s) are often not ready when pivotal trials commence, and it is common to have drug product changes (manufacturing process or presentation) during clinical dev...
متن کاملClinical drug development--practical issues in clinical pharmacology studies.
INTRODUCTION Clinical pharmacology refers to the study of the safety, pharmacodynamic activity, mechanism of action, pharmacokinetics, metabolism and excretion of a drug in man. METHODS Selected review of topics that provide guidance on practical issues for researchers conducting non-therapeutic investigational research in humans. RESULTS Close attention to the issues highlighted is needed ...
متن کاملClinical effectiveness of biologics in clinical practice
TNF inhibitors are currently considered both effective and cost-effective in patients with active rheumatoid arthritis (RA), particularly in patients who have not responded fully to methotrexate. There is substantial doubt about the cost-effectiveness of TNF inhibitors as initial treatment for active RA. New data from the National Data Bank for Rheumatic Diseases now question the current consen...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Acta Pharmacologica Sinica
سال: 2012
ISSN: 1671-4083,1745-7254
DOI: 10.1038/aps.2012.51